Ashish M. Kamat, President of IBCG, Associated Editor at European Urology Oncology, shared a post on X:
“Debate 6 at the IBCG, Amer. Urol. Assn., Bladder Cancer Forum May 17, 2-5pm.
Systemic therapy in MIBC: follow the protocol or use risk-adapted therapy?
Andrea Necchi: Sandwich therapy is the standard. Niagara and KN-905 have spoken.
Félix Guerrero-Ramos: Risk-adapted adjuvant therapy is smarter. Treating everyone the same is overtreating some. ctDNA enters the chat.
Shilpa Gupta moderates.”
To which Shilpa Gupta, Director of Genitourinary Oncology at the Cleveland Clinic, added:
“Looking forward to moderating an exciting debate in the new era of EV-P in MIBC. ”
Other articles featuring Ashish M. Kamat and Shilpa Gupta on OncoDaily.